Sack Stefan
Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin, Klinikum Schwabing, Städtisches Klinikum München GmbH, München, Germany.
Herz. 2009 Sep;34(6):468-76. doi: 10.1007/s00059-009-3287-5.
Functional mitral regurgitation (MR) in heart failure patients limits survival in a severity-graded fashion. Even mild MR doubles the mortality risk. The use of a nonstented coronary sinus device to reduce mitral annulus dimension in order to reestablish mitral valve competence is reported. The device (PTMA, Viacor, Inc., Wilmington, MA, USA) consists of a multilumen PTFE (Teflon) PTMA catheter in which nitinol (nickel-titanium alloy) treatment rods are advanced. For individual treatment, up to three rods of different length and stiffness can be used. Therefore, dimension reduction can be performed in an incremental fashion. Fluoroscopy and three-dimensional (3-D) echocardiography are performed through the procedure to visualize the positioning and confirm maximum treatment effect. This report describes an implant case and summarizes the safety and feasibility of the new PTMA treatment device in 27 patients. The cases reflect the learning curve in both device design and implantation technique. In permanent implant, a sustained reduction of mitral annulus septal-lateral dimension from 3-D echo reconstruction dimensions was observed (4.9 +/- 1.2 mm at 3 months).
心力衰竭患者的功能性二尖瓣反流(MR)以严重程度分级的方式限制生存。即使是轻度MR也会使死亡风险加倍。据报道,使用无支架冠状静脉窦装置来减小二尖瓣环尺寸,以重建二尖瓣功能。该装置(PTMA,Viacor公司,美国马萨诸塞州威尔明顿)由一根多腔聚四氟乙烯(特氟龙)PTMA导管组成,其中推进了镍钛诺(镍钛合金)治疗棒。对于个体治疗,可使用多达三根不同长度和硬度的棒。因此,可以以递增方式进行尺寸减小。在整个过程中进行荧光透视和三维(3-D)超声心动图检查,以可视化定位并确认最大治疗效果。本报告描述了一例植入病例,并总结了新型PTMA治疗装置在27例患者中的安全性和可行性。这些病例反映了在装置设计和植入技术方面的学习曲线。在永久性植入中,观察到三维超声心动图重建尺寸显示二尖瓣环间隔-侧方尺寸持续减小(3个月时为4.9±1.2毫米)。